QUECTEL-WIRELESS
14.11.2022 09:01:38 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces its expanded Wi-Fi module portfolio with the launch of the FC6xE series of Wi-Fi/Bluetooth modules, based on Qualcomm’s QCA206x Wi-Fi 6E chip. Designed to deliver faster, more secure, and more robust Wi-Fi experiences than ever before, the FC6xE also features Bluetooth audio functionality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221113005138/en/
Quectel announces extended Wi-Fi 6/6E module portfolio to address home and commercial environments (Photo: Business Wire)
Supporting 2 × 2 MIMO and DBS, the FC6xE family provides a maximum data rate up to 3000 Mbps. With a compact and unified form factor of 19.9 mm × 18.0 mm × 2.1 mm, the FC6xE modules are the optimal Wi-Fi/Bluetooth solution for size-sensitive applications and can help customers reduce product size and optimize application design cost.
“Targeting the nascent Wi-Fi 6/6E market, the FC62E, FC64E, FC65E and FC66E all offer superior Wi-Fi 6/6E performance,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "When used in combination with Quectel 5G modules, they also deliver best-in-class 5G functionality, guaranteeing ultra-reliable connections for a wide range of multi-user scenarios including smart homes, shopping malls, schools and factories.”
The modules join an already extensive range of Wi-Fi/Bluetooth modules delivering functionality across Wi-Fi 4, Wi-Fi 5, Wi-Fi 6, and Wi-Fi 6E.
RF Wi-Fi/Bluetooth modules
- FC20/21 - typically used in connecting with different Linux/Android application processors, the compact form factor, low power consumption, extended temperature range and stable SDIO interface allow this module to serve a wide range of IoT applications including consumer, safety, industrial, mobile hotspots and healthcare.
- FC80A - a high-performance Wi-Fi 5 module, supporting 2.4GHz and 5GHz RSDB (Real simultaneous dual band) and Bluetooth 5.1, the FC80A can meet the Wi-Fi & Bluetooth application design requirements expected across consumer fields including set top boxes and VR.
- FC909A - with a reliable SDIO 2.0 interface enabling WLAN capability, the FC909A also provides BT functions with low power consumption, making it ideal for mobile devices requiring battery powered and compact size.
MCU Wi-Fi/Bluetooth Modules
- FC41D - Based on a standalone Wi-Fi & Bluetooth chip, the FC41D can offer diversified applications for customers. Combined with its ultra-compact size, low power consumption, ultra-wide temperature range and high reliability, FC41D can meet the requirements of low flow control and data acquisition applications such as smart homes and industrial control.
The hosted range of Wi-Fi/Bluetooth modules are ideal for both home and commercial applications including set top boxes, smart TVs, and smart speakers in the home and POS, scanner, and printer applications in a business environment. The hosted range is also appropriate for a wide range of telematics applications. The MCU Wi-Fi/Bluetooth module is typically used as a connectivity link between IoT devices and public or private cloud.
Complementing the FC6xE modules are a range of antennas across the 2.4Ghz and 6Ghz spectrum including the YF0026AA FPC, YF0027AA FPC, YF0023AA FR4 and YEWT004AA while additional antennas can support 5Ghz spectrum.
For more information on the Quectel range of Wi-Fi/Bluetooth modules, head over to our website: https://www.quectel.com/wifi-iot-modules
For more information on Quectel antennas: https://www.quectel.com/product-category/antennas
Download our Wi-Fi 6 white paper: https://www.quectel.com/library/wifi-6-white-paper
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005138/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom